6-Methyl-n-{[1-(methylamino)cyclopropyl]methyl}pyridin-3-amine | 922337-55-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-Methyl-n-{[1-(methylamino)cyclopropyl]methyl}pyridin-3-amine
• 英文别名: 6-methyl-N-[[1-(methylamino)cyclopropyl]methyl]pyridin-3-amine
• CAS: 922337-55-1
• 化学式: C₁₁H₁₇N₃
• 分子量: 191.27
• InChiKey: RDZAOJGWNFAXSV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  37
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Polysubstituted 1,1-pyridylamioncyclopropanamine compounds
  申请人：Goldstein Solo

  公开号：US20070027192A1

  公开（公告）日：2007-02-01

  A compound selected from those of formula (I): wherein: n represents an integer from 1 to 6 inclusive, R 1 and R 2 represent a hydrogen atom, a (C 1 -C 6 )alkyl group or an aryl-(C 1 -C 6 )alkyl group, R 3 and R 4 represent a hydrogen atom or a (C 1 -C 6 )alkyl group, R 5 and R 6 represent a hydrogen atom or a (C 1 -C 6 )alkyl, halogen, hydroxy, (C 1 -C 6 )alkoxy, cyano, nitro, (C 2 -C 6 )acyl, (C 1 -C 6 )alkoxycarbonyl, (C 1 -C 6 )trihaloalkyl or (C 1 -C 6 )-trihaloalkoxy group or an optionally substituted amino group, R 7 represents a hydrogen atom, a (C 1 -C 6 )alkyl group or an arylalkyl group, its enatiomers, diastereoisomers and additional salts thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful in the treatment of conditions requiring a specific nicotinic ligand of α4β2 receptors.

  从公式（I）中选择的一种化合物：其中：n表示1到6之间的整数，R1和R2表示氢原子，（C1-C6）烷基或芳基-（C1-C6）烷基，R3和R4表示氢原子或（C1-C6）烷基，R5和R6表示氢原子或（C1-C6）烷基，卤素，羟基，（C1-C6）烷氧基，氰基，硝基，（C2-C6）酰基，（C1-C6）烷氧羰基，（C1-C6）三卤代烷基或（C1-C6）-三卤代烷氧基或可选择取代的氨基团，R7表示氢原子，（C1-C6）烷基或芳基烷基，其对映异构体，非对映异构体及其与药学上可接受的酸或碱形成的额外盐。含有这种化合物的药物制剂对需要特定α4β2受体的烟碱配体治疗的病症有用。
• Heteroaromatic derivatives having an inhibitory activity against HIV integrase
  申请人：——

  公开号：US20040002485A1

  公开（公告）日：2004-01-01

  A compound of the formula (I): 1 wherein X is hydroxy, protected hydroxy or optionally substituted amino; Y is —COOR A wherein R A is hydrogen or ester residue, —CONR B R C wherein R B and R C each is independently hydrogen or amide residue, optionally substituted aryl or optionally substituted heteroaryl; and A 1 is optionally substituted heteroaryl; provided that a compound wherein Y and/or A 1 is optionally substituted indol-3-yl is excluded, a tautomer, a prodrug, a pharmaceutically acceptable salt or a hydrate thereof has an inhibitory activity against an integrase.

  式(I)的化合物：其中X为羟基，保护羟基或可选取代的氨基；Y为—COORA，其中RA为氢或酯基残基，—CONRBRC，其中RB和RC各自独立地为氢或酰胺基残基，可选取代的芳基或可选取代的杂芳基；且A1为可选取代的杂芳基；但其中Y和/或A1为可选取代的吲哚-3-基的化合物被排除，其互变异构体、前药、药物可接受的盐或水合物具有对整合酶的抑制活性。
• Polysubstituted 1,1-pyridylaminocyclopropanamine compounds
  申请人：Goldstein Solo

  公开号：US20080146621A1

  公开（公告）日：2008-06-19

  A compound selected from those of formula (1): wherein: n represents an integer from 1 to 6 inclusive, R 1 and R 2 represent a hydrogen atom, a (C 1 -C 6 )alkyl group or an aryl-(C 1 -C 6 )alkyl group, R 3 and R 4 represent a hydrogen atom or a (C 1 -C 6 )alkyl group, R 5 and R 6 represent a hydrogen atom or a (C 1 -C 6 )alkyl, halogen, hydroxy, (C 1 -C 6 )alkoxy, cyano, nitro, (C 2 -C 6 )acyl, (C 1 -C 6 )alkoxycarbonyl, (C 1 -C 6 )trihaloalkyl or (C 1 -C 6 )-trihaloalkoxy group or an optionally substituted amino group, R 7 represents a hydrogen atom, a (C 1 -C 6 )alkyl group or an arylalkyl group, its enantiomers, diastereoisomers and additional salts thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful in the treatment of conditions requiring a specific nicotinic ligand of α4β2 receptors.

  从公式（1）中选择的化合物，其中：n表示1到6之间的整数，R1和R2表示氢原子，（C1-C6）烷基或芳基-（C1-C6）烷基，R3和R4表示氢原子或（C1-C6）烷基，R5和R6表示氢原子或（C1-C6）烷基，卤素，羟基，（C1-C6）烷氧基，氰基，硝基，（C2-C6）酰基，（C1-C6）烷氧羰基，（C1-C6）三卤代烷基或（C1-C6）三卤代烷氧基，或者是一个可选取代的氨基基团，R7表示氢原子，（C1-C6）烷基或芳基烷基，其对应的对映异构体，差向异构体和药学上可接受的酸或碱的额外盐。含有该化合物的药物产品在需要特定的α4β2受体的尼古丁配体治疗的疾病中有用。
• AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES
  申请人：SHIONOGI & CO., LTD.

  公开号：EP1142872A1

  公开（公告）日：2001-10-10

  A compound of the formula (I): wherein X is hydroxy, protected hydroxy or optionally substituted amino; Y is COORA wherein RA is hydrogen or ester residue, -CONRBRC wherein RB and RC each is independently hydrogen or amide residue, optionally substituted aryl or optionally substituted heteroaryl; and A1 is optionally substituted heteroaryl; provided that a compound wherein Y and/or A1 is optionally substituted indol-3-yl is excluded, a tautomer, a prodrug, a pharmaceutically acceptable salt or a hydrate thereof has an inhibitory activity against an integrase.

  一种式（I）化合物： 其中 X 是羟基、受保护的羟基或任选取代的氨基；Y 是 COORA（其中 RA 是氢或酯残基）、-CONRBRC（其中 RB 和 RC 各自独立地是氢或酰胺残基）、任选取代的芳基或任选取代的杂芳基；以及 A1 是任选取代的杂芳基；条件是其中 Y 和/或 A1 是任选取代的吲哚-3-基的化合物除外，其同分异构体、原药、药学上可接受的盐或水合物对整合酶具有抑制活性。
• Nouveaux composés 1,1-pyridinylaminocyclopropanamines polysubstitués, leur procédé de préparation et les compositions pharmaceutiques yui les contiennent
  申请人：Les Laboratoires Servier

  公开号：EP1757586B1

  公开（公告）日：2008-12-03